Novel Ru(III), Rh(III), Pd(II) and Pt(II) complexes with ligands incorporating azole and pyrimidine rings. I. Antiproliferative activity in vitro.
A number of co-ordination compounds of Ru(III), Rh(III), Pd(II) and Pt(II) with ligands incorporating azole and pyrimidine rings has been synthesized. The in vitro cell proliferation-inhibitory activity of these compounds was examined against human cancer cell lines: A 549 (lung carcinoma), LS-180 (colon cancer) and MCF-7 (breast cancer), using SRB technique. Six out of 13 compounds studied revealed cytotoxic activity in vitro. Inhibitory dose 50% (ID50) was lower than 4 microg/ml, which is an activity criterion accepted in conventional in vitro cytotoxic screening tests. Two compounds revealed weak cytotoxic activity with ID50 higher than 4 microg/ml and five compounds were inactive.
Wiśniewski
M Z
MZ
Institute of Chemistry, Pedagogical University, Kielce, Poland.
Wietrzyk
J
J
Opolski
A
A
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D019216:Metals, Heavy; D009942:Organometallic Compounds / Q000737:chemistry / Q000494:pharmacology*; D009944:Organoplatinum Compounds / Q000494:pharmacology; D010165:Palladium / Q000494:pharmacology; D012238:Rhodium / Q000494:pharmacology; D012428:Ruthenium / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D008024:Ligands; D019216:Metals, Heavy; D009942:Organometallic Compounds; D009944:Organoplatinum Compounds; D010165:Palladium; D012428:Ruthenium; D012238:Rhodium